Hussein Abbas, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that uses CD8 profiling to investigate if a CD8-exhausted phenotype in acute myeloid leukemia (AML) could be an explanation for treatment resistance. The study reveals that CD8-expressing T-cells do not show signs of being exhausted, but there are other dysfunctional signatures that are upregulated and persist after chemotherapy, contributing to treatment resistance. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.